Press Coverage and Latest Announcements


November 18, 2022
Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi’s AI Liquid Biopsy Platform

October 26, 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022

September 12, 2022
Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study

August 23, 2022
Delfi Diagnostics Adds Finance and Market Access Leadership as it Prepares for Commercial Launch

July 18, 2022
Delfi Diagnostics Announces $225M Series B Financing

July 12, 2022
Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer

June 22, 2022
Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directors

May 26, 2022
Delfi Diagnostics to Present at 2022 ASCO Annual Meeting on Multiple Applications for its Next-Generation Liquid Biopsy Platform

May 17, 2022
Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center

May 9, 2022
Delfi Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial

April 4, 2022
Delfi Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

March 30, 2022
Delfi Diagnostics Appoints Liz Homans to its Board of Directors

March 24, 2022
Delfi Diagnostics Adds Reimbursement, Regulatory Leaders to Management Team

October 21, 2021
Delfi Bolsters Leadership Team with Three Key Hires

October 7, 2021
Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officer

August 20, 2021
Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths

June 23, 2021
Dr. Peter Bach Joins Delfi Diagnostics as Chief Medical Officer

March 31, 2021
Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer
Screening Trial Ahead of Planned Commercial Test

February 17, 2021
Industry Leaders Tara Maddala and Allison Ryan Join Delfi Diagnostics Leadership Team

January 16, 2021
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers